|
KMID : 0615720140310010095
|
|
Jouranl of Korean Acupuncture and Moxibustion society
2014 Volume.31 No. 1 p.95 ~ p.103
|
|
|
Effects of Paljeong-san Pharmacopuncture on Experimental Rat Model of Benign Prostatic Hyperplasia
|
|
Kim Chae-Won
Lee Kwang-Ho
|
|
|
Abstract
|
|
|
Objectives : The aim of this study is to evaluate the effect of Paljeong-san pharmacopuncture(PJS) on the rat model of benign prostatic hyperplasia(BPH).
Methods : Rats were divided into 5 groups, with 6 rats in each group. The 5 groups included sham-operated group(sham group), BPH model group(BPH group), finasteride-treated group (fina group), PJS-treated groups(PJS 10 and PJS 100 group). Testosterone was injected subcutaneously to the castrated rats except sham group for BPH model. During 4-week experimental period, finasteride(5 mg/kg) was administrated orally once daily in fina group, PJS in PJS 10(10 mg/kg) and PJS 100(100 mg/kg) group and normal saline in sham and BPH group were injected subcutaneously once daily at Jungwan(CV12).
We checked prostate weights, serum concentration of dihydrotestosterone(DHT), morphologic changes of the prostate, and the amount of expression of the proliferating cell nuclear antigen(PCNA) and 5α-reductase gene to evaluate the effect of PJS after 4-week experimental period.
Results : 1.PJS and finasteride treatment reduced prostate weights comparing with BPH group, but PJS-treated groups showed no significant changes, unlikely fina group.
2.PJS-treated groups showed significant degreases in concentration of DHT.
3.PJS-treated groups showed significant degreases concentration-dependently in the amount of expression of the PCNA and 5α-reductase gene.
4.PJS treatment showed shrinking of thickness in the prostatic epithelial tissue.
Conclusions : PJS has the effects that improve the symptoms of BPH through inhibiting proliferation of the prostatic tissues.
|
|
|
KEYWORD
|
|
|
Benign prostatic hyperplasia, Paljeong-san, Pharmacopuncture, Finasteride
|
|
|
FullTexts / Linksout information
|
|
 
|
|
|
Listed journal information
|
|
|
|